Showing 5661-5670 of 5949 results for "".
- Live Cosmetic Surgery Workshop This Septemberhttps://practicaldermatology.com/news/20130812-live_cosmetic_surgery_workshop_this_september/2459480/Dr. Joe Niamtu, III will present the 2013 Ultimate Facial Rejuvenation Live Cosmetic Surgery Workshop September 20-22. The course will include lectures and live surgeries on:facelift and facial liposuction, browlift, eyelid surgery, facial implants, laser resurfacing, chemical peels, fillers, mole r
- AARS Hosting Acne and Rosacea Bootcamp September 6-8, 2013https://practicaldermatology.com/news/20130809-aars_hosting_acne_and_rosacea_bootcamp_september_6-8_2013/2459481/The American Acne and Rosacea Society (AARS) is hosting the Acne and Rosacea Bootcamp, a two-day CME event open to all medical health professionals involved in the management of acne and rosacea. The program will be held September 6-8, 2013 at the Hyatt Chicago Magnificent Mile. This event will p
- Differin Gel Found Effective in Adult Women with Acnehttps://practicaldermatology.com/news/20130807-differin_gel_found_effective_in_adult_women_with_acne/2459483/At the recent AAD Summer Meeting in New York, Galderma Laboratories presented results showing that Differin® (adapalene) Gel, 0.3% is efficacious in reducing acne lesions in adult women, and has been proven superior in reducing inflammatory lesions in women compared with vehicle gel. Investigators u
- Merz Acquires Neocutis' Skin Care Divisionhttps://practicaldermatology.com/news/20130801-merz_acquires_neocutis/2459486/Merz Pharma Group has acquired the cosmetics, over-the-counter, and prescription skin care businesses of Swiss dermatology company Neocutis. The company's North American division will integrate marketing of Neocutis' line of physician-dispensed topical skin care products in the US. “Neocutis' line
- Valeant Unveils Advanced Deep Cleansing Duo for Acnehttps://practicaldermatology.com/news/20130730-valeant_unveils_advanced_deep_cleansing_duo_for_acne/2459487/Valeant Pharmaceuticals is has added additional products to its new AcneFree product line. Rounding out AcneFree's daily cleansing option are the AcneFree Advanced Cleansing Brush and AcneFree Oil-Free Purifying Cleanser. The Cleansing Brush features a two-speed rotating brush head to exfoliate and
- LEO Launches Taclonex in Larger Package Sizehttps://practicaldermatology.com/news/20130730-leo_launches_taclonex_in_larger_package_size/2459488/LEO Pharma Inc., has launched a patient-friendly 120g package size of Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of plaque psoriasis.
- FDA Limits Use of Nizoralhttps://practicaldermatology.com/news/20130730-fda_limits_use_of_nizoral/2459489/The FDA has limited the use of Nizoral (ketoconazole) oral tablets, warning that the oral tablets can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Gu
- Positive Findings Published for Provectus Pharmaceuticals' PV-10https://practicaldermatology.com/news/20130726-positive_findings_published_for_provectus_pharmaceuticals_pv-10/2459491/Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication,
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- European Commission Grants Conditional Approval to Erivedgehttps://practicaldermatology.com/news/20130716-european_commission_grants_conditional_approval_to_erivedge/2459497/The European Commission has granted conditional approval to Erivedge (vismodegib) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy. The Commission granted the conditional approval based upon t